| Ibrutinib‐associated bleeding: pathogenesis, management and risk reduction strategies JJ Shatzel, SR Olson, DL Tao, OJT McCarty, AV Danilov, TG DeLoughery Journal of thrombosis and haemostasis 15 (5), 835-847, 2017 | 254 | 2017 |
| Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours C Serrano, A Mariño-Enríquez, DL Tao, J Ketzer, G Eilers, M Zhu, C Yu, ... British journal of cancer 120 (6), 612-620, 2019 | 144 | 2019 |
| STAT6 is amplified in a subset of dedifferentiated liposarcoma LA Doyle, D Tao, A Mariño-Enríquez Modern Pathology 27 (9), 1231-1237, 2014 | 136 | 2014 |
| Frequent expression of KIT in endometrial stromal sarcoma with YWHAE genetic rearrangement CH Lee, LN Hoang, S Yip, C Reyes, A Marino-Enriquez, G Eilers, D Tao, ... Modern Pathology 27 (5), 751-757, 2014 | 70 | 2014 |
| Aspirin and antiplatelet treatments in cancer DL Tao, S Tassi Yunga, CD Williams, OJT McCarty Blood, The Journal of the American Society of Hematology 137 (23), 3201-3211, 2021 | 58 | 2021 |
| CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans G Eilers, JT Czaplinski, M Mayeda, N Bahri, D Tao, M Zhu, JL Hornick, ... Molecular cancer therapeutics 14 (6), 1346-1353, 2015 | 50 | 2015 |
| Financial conflicts of interest among hematologist-oncologists on Twitter DL Tao, A Boothby, J McLouth, V Prasad JAMA Internal Medicine 177 (3), 425-427, 2017 | 46 | 2017 |
| Antithrombotic therapies in COVID-19 disease: a systematic review E Maldonado, D Tao, K Mackey Journal of general internal medicine 35, 2698-2706, 2020 | 45 | 2020 |
| Conflicts of interest in Twitter V Kaestner, A Brown, D Tao, V Prasad The Lancet Haematology 4 (9), e408-e409, 2017 | 23 | 2017 |
| Extended thromboprophylaxis with direct oral anticoagulants for medical patients: a systematic review and meta-analysis DL Tao, JY Bien, TG DeLoughery, JJ Shatzel Blood, The Journal of the American Society of Hematology 129 (5), 653-655, 2017 | 21 | 2017 |
| The efficacy and safety of DOACs versus LMWH for cancer-associated thrombosis: a systematic review and meta-analysis DL Tao, SR Olson, TG DeLoughery, JJ Shatzel European journal of haematology 105 (3), 360, 2020 | 18 | 2020 |
| Assessing the risk of thromboembolism in cancer patients receiving immunotherapy A Goel, A Khorana, T Kartika, S Gowda, DL Tao, R Thawani, JJ Shatzel European journal of haematology 108 (4), 271-277, 2022 | 14 | 2022 |
| Choice of control group in randomised trials of cancer medicine: are we testing trivialities? D Tao, V Prasad The Lancet Oncology 19 (9), 1150-1152, 2018 | 13 | 2018 |
| Phase I trials and therapeutic intent in the age of precision oncology: what is a patient's chance of response? DL Tao, T Kartika, A Tran, V Prasad European Journal of Cancer 139, 20-26, 2020 | 12 | 2020 |
| Molecular testing in patients with castration-resistant prostate cancer and its Impact on clinical decision making DL Tao, S Bailey, TM Beer, E Foss, B Beckett, A Fung, BR Foster, ... JCO precision oncology 1, 1-11, 2017 | 10 | 2017 |
| Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. KY Lai, SY Au, KM Fong N Engl J Med, e11-e11, 2021 | 7 | 2021 |
| The safety of aspirin vs. direct oral anticoagulants: a meta-analysis of currently published clinical trials JY Bien, MM Daughety, DL Tao, TG Deloughery, JJ Shatzel Blood, The Journal of the American Society of Hematology 130 (Suppl_1), 3720 …, 2017 | 5 | 2017 |
| Multiplicity and the marginal benefits of bevacizumab in malignant solid tumours V Prasad Current Oncology 26 (6), 791-792, 2019 | 4 | 2019 |
| The tradeoff of cancer drug regulatory policy: faster approvals for one means less knowledge for another D Tao, S Schott, V Prasad The American journal of medicine 132 (3), e509-e511, 2019 | 4 | 2019 |
| Association of PD-L1 expression, tumor mutational burden and immunotherapy with venous thrombosis in patients with solid organ malignancies R Thawani, T Kartika, B Elstrott, E Batiuk, D Tao, S Gowda, L Chen, ... Thrombosis research 217, 12-14, 2022 | 3 | 2022 |
Joseph ShatzelOregon Health & Science UniversityAdresse e-mail validée de ohsu.edu
